Another clinical trial initiated by Grifols (ClinicalTrials.gov Identifier: NCT01561053, NCT00742417) showed that the plasma exchange (PE) with the replacement of human serum albumin significantly slow the functional decline in patients with Alzheimer’s disease based on the Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scales. The gene discussed is ALB; the disease is early-onset autosomal dominant Alzheimer disease.